Senti Biosciences Inc. (NASDAQ: SNTI) stock jumped 6.16% on Wednesday to $2.24 against a previous-day closing price of $2.11. With 74885.0 shares changed hands, the volume of the stock remained lighter than its average volume of 4.75 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $2.2900 whereas the lowest price it dropped to was $2.0900. The 52-week range on SNTI shows that it touched its highest point at $10.35 and its lowest point at $1.20 during that stretch. It currently has a 1-year price target of $8.83.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of SNTI was down-trending over the past week, with a drop of -6.67%, but this was down by -15.79% over a month. Three-month performance surged to 12.00% while six-month performance fell -77.46%. The stock lost -77.58% in the past year, while it has lost -77.28% so far this year. A look at the trailing 12-month EPS for SNTI yields -0.17 with Next year EPS estimates of -1.63.
Float and Shares Shorts:
At present, 29.47 million SNTI shares are outstanding with a float of 24.88 million shares on hand for trading. On Oct 30, 2022, short shares totaled 0.52 million, which was 1.18% higher than short shares on Sep 29, 2022. In addition to Dr. Timothy K. Lu M.D., Ph.D. as the firm’s Co-founder, CEO, Pres & Director, Dr. Philip Lee Ph.D. serves as its Co-Founder & CTO.
Through their ownership of 32.19% of SNTI’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 6.16% of SNTI, in contrast to 4.02% held by mutual funds. Shares owned by individuals account for 14.46%. As the largest shareholder in SNTI with 9.18% of the stake, T. Rowe Price Associates, Inc. holds 4,015,483 shares worth 4,015,483. A second-largest stockholder of SNTI, ARK Investment Management LLC, holds 2,087,696 shares, controlling over 4.77% of the firm’s shares. Invus Public Equities Advisors LL is the third largest shareholder in SNTI, holding 1,055,555 shares or 2.41% stake. With a 4.56% stake in SNTI, the ARK Genomic Revolution ETF is the largest stakeholder. A total of 1,993,836 shares are owned by the mutual fund manager. The T Rowe Price Health Sciences Fund, which owns about 3.55% of SNTI stock, is the second-largest Mutual Fund holder. It holds 1,551,383 shares valued at 3.6 million. T Rowe Price New Horizons Fund holds 3.34% of the stake in SNTI, owning 1,462,032 shares worth 3.39 million.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Sep 29, 2022, SNTI reported revenue of $1.11M and operating income of -$21.77M. The EBITDA in the recently reported quarter was -$31.94M and diluted EPS was -$0.86.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for SNTI since 3 analysts follow the stock currently. There are 2 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With SNTI analysts setting a high price target of $12.00 and a low target of $7.00, the average target price over the next 12 months is $8.83. Based on these targets, SNTI could surge 435.71% to reach the target high and rise by 212.5% to reach the target low. Reaching the average price target will result in a growth of 294.2% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.. Analysts have provided yearly estimates in a range of -$1.38 being high and -$2.69 being low. For SNTI, this leads to a yearly average estimate of -$2.07. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Senti Biosciences Inc. surprised analysts by $0.08 when it reported -$0.38 EPS against a consensus estimate of -$0.46. Based on analyst estimates, the high estimate for the next quarter is -$0.35 and the low estimate is -$0.52. The average estimate for the next quarter is thus -$0.46.
Summary of Insider Activity:
Insiders traded SNTI stock several times over the past three months with 1 Buys and 0 Sells. In these transactions, 30,000 shares were bought while 0 shares were sold. The number of buy transactions has increased to 4 while that of sell transactions has risen to 2 over the past year. The total number of shares bought during that period was 11,642,519 while 10,983,597 shares were sold.